Prevalence of (A) any hearing loss and (B) severe hearing loss and (C) degree of hearing loss by exposure and grading scale; (D) percentage of children requiring a hearing aid by exposure. ASHA, American Speech-Language-Hearing Association; CTCAEv3, Common Terminology Criteria for Adverse Events, version 3; Exp 1, exposure one (cisplatin ≤ 400 mg/m2); Exp 2, exposure two (cisplatin 400 mg/m2 and carboplatin 1,700 mg/m2).